A Phase.b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage

被引：0
|
作者：
Wang, Jiayu
Sun, Tao
Zhang, Qingyuan
Shi, Yanxia
Wang, Xu
Chen, Yiding
Ouyang, Quchang
Li, Kunyan
Bupathi, Manojkumar
Edenfield, W. Jeffery
Silber, Andrea L. M.
Zong, Hong
Hamilton, Erika
Juric, Dejan
Lathrop, Kate
Zhang, Yihong
Stazzone, Kathryn
Shi, Zhe
Wang, Yaolin
Zhang, Ling
Xu, Binghe
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS15-02
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [42] Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B
    Masuda, Hiroko
    Iwasa, Tsutomu
    Mukohara, Toru
    Tokunaga, Shinya
    Matsumoto, Koji
    Niikura, Naoki
    Sagara, Yasuaki
    Miyoshi, Yasuo
    Shimomura, Akihiko
    Takahashi, Masato
    Nagashima, Takeshi
    Doi, Mihoko
    Futamura, Manabu
    Yoshimura, Kenichi
    Takano, Toshimi
    Tsurutani, Junji
    CANCER RESEARCH, 2020, 80 (04)
  • [43] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [44] Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer
    McCartney, Amelia
    Benelli, Matteo
    Di Leo, Angelo
    BREAST, 2019, 48 : S81 - S84
  • [45] A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
    Chan, Arlene
    Day, Daphne
    Phuong Dinh
    Slancar, Michael
    Lombard, Janine
    Ganju, Vinod
    McCarthy, Nicole
    Wilson, Rosalind
    Faltaos, Demiana
    Mathauda-Sahota, Gurpreet
    Murphy, Caitlin
    CANCER RESEARCH, 2024, 84 (09)
  • [46] A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER-positive, HER2-negative, postmenopausal advanced breast cancer patients.
    Harb, Wael A.
    Garner, Fiona
    Clarkin, Marcie
    Roberge, Kathleen A.
    Harris, Alan G.
    Williams, Gregory
    Hattersley, Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review
    Qureshi, Zaheer
    Jamil, Abdur
    Altaf, Faryal
    Siddique, Rimsha
    Adilovic, Edin
    Fatima, Eeshal
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4624 - 4633
  • [48] The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
    Thibodeau, Stephane
    Voutsadakis, Ioannis A.
    EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (03) : 163 - 170
  • [49] EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
    Dubsky, P.
    Filipits, M.
    Jakesz, R.
    Rudas, M.
    Singer, C. F.
    Greil, R.
    Dietze, O.
    Luisser, I.
    Klug, E.
    Sedivy, R.
    Bachner, M.
    Mayr, D.
    Schmidt, M.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Kronenwett, R.
    Brase, J. C.
    Gnant, M.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 640 - 647
  • [50] Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
    Chan, Arlene
    Day, Daphne
    Hui, Rina
    McCarthy, Nicole
    Wilson, Rosalind
    Faltaos, Demiana
    Shaw, Morena
    Murphy, Caitlin
    CANCER RESEARCH, 2023, 83 (05)
12345